These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 19208845

  • 1. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y, Tong C, Zhang J, Nakamura T, Iankov I, Russell SJ, Merchan JR.
    Cancer Res; 2009 Feb 15; 69(4):1459-68. PubMed ID: 19208845
    [Abstract] [Full Text] [Related]

  • 2. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
    Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X, Merchan JR.
    Mol Cancer Res; 2017 Oct 15; 15(10):1410-1420. PubMed ID: 28679779
    [Abstract] [Full Text] [Related]

  • 3. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y, Bejarano MT, Zaias J, Merchan JR.
    Breast Cancer Res Treat; 2015 Jan 15; 149(1):99-108. PubMed ID: 25519042
    [Abstract] [Full Text] [Related]

  • 4. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y, Zaias J, Duncan R, Russell SJ, Merchan JR.
    Gene Ther; 2014 Mar 15; 21(3):289-97. PubMed ID: 24430235
    [Abstract] [Full Text] [Related]

  • 5. Oncolytic measles virus retargeting by ligand display.
    Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E.
    Methods Mol Biol; 2012 Mar 15; 797():141-62. PubMed ID: 21948475
    [Abstract] [Full Text] [Related]

  • 6. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C.
    Gene Ther; 2013 Mar 15; 20(3):338-47. PubMed ID: 22717740
    [Abstract] [Full Text] [Related]

  • 7. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E, Kurokawa C, Viker K, Ammayappan A, Anderson SK, Sotiriou S, Chatzopoulos K, Ayasoufi K, Johnson AJ, Iankov ID, Galanis E.
    J Clin Invest; 2021 Jul 01; 131(13):. PubMed ID: 34196308
    [Abstract] [Full Text] [Related]

  • 8. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
    Hum Gene Ther; 2013 Jul 01; 24(7):644-54. PubMed ID: 23642239
    [Abstract] [Full Text] [Related]

  • 9. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.
    Jing Y, Chavez V, Khatwani N, Ban Y, Espejo AP, Chen X, Merchan JR.
    Cancer Gene Ther; 2020 Dec 01; 27(12):910-922. PubMed ID: 32231231
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
    Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E.
    Mol Ther; 2008 Sep 01; 16(9):1556-64. PubMed ID: 18665158
    [Abstract] [Full Text] [Related]

  • 11. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
    Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E.
    Cancer Res; 2006 Dec 15; 66(24):11840-50. PubMed ID: 17178881
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
    Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E.
    Mol Ther; 2007 Apr 15; 15(4):677-86. PubMed ID: 17299404
    [Abstract] [Full Text] [Related]

  • 14. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF.
    Hepatology; 2006 Dec 15; 44(6):1465-77. PubMed ID: 17133484
    [Abstract] [Full Text] [Related]

  • 15. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E.
    Prostate; 2009 Jan 01; 69(1):82-91. PubMed ID: 18973133
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW.
    Prostate; 2009 Jul 01; 69(10):1128-41. PubMed ID: 19367568
    [Abstract] [Full Text] [Related]

  • 17. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AW.
    BMC Cancer; 2014 Mar 19; 14():206. PubMed ID: 24646176
    [Abstract] [Full Text] [Related]

  • 18. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
    Ayala-Breton C, Barber GN, Russell SJ, Peng KW.
    Hum Gene Ther; 2012 May 19; 23(5):484-91. PubMed ID: 22171635
    [Abstract] [Full Text] [Related]

  • 19. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
    Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ.
    Cancer Gene Ther; 2010 Aug 19; 17(8):550-8. PubMed ID: 20379224
    [Abstract] [Full Text] [Related]

  • 20. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
    Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW.
    Mol Ther; 2013 Oct 19; 21(10):1930-7. PubMed ID: 23842448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.